Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Operating Leases (2023 - 2026)

Beta Bionics' Operating Leases history spans 4 years, with the latest figure at $5.1 million for Q1 2026.

  • On a quarterly basis, Operating Leases fell 6.92% to $5.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.1 million, a 6.92% decrease, with the full-year FY2025 number at $5.4 million, down 6.3% from a year prior.
  • Operating Leases hit $5.1 million in Q1 2026 for Beta Bionics, down from $5.4 million in the prior quarter.
  • Over the last five years, Operating Leases for BBNX hit a ceiling of $5.7 million in Q4 2024 and a floor of $3.0 million in Q4 2023.
  • Historically, Operating Leases has averaged $5.1 million across 4 years, with a median of $5.4 million in 2025.
  • Biggest five-year swings in Operating Leases: soared 90.93% in 2024 and later dropped 6.92% in 2026.
  • Tracing BBNX's Operating Leases over 4 years: stood at $3.0 million in 2023, then soared by 90.93% to $5.7 million in 2024, then fell by 6.3% to $5.4 million in 2025, then decreased by 5.44% to $5.1 million in 2026.
  • Business Quant data shows Operating Leases for BBNX at $5.1 million in Q1 2026, $5.4 million in Q4 2025, and $5.7 million in Q3 2025.